Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.37 |
| ▸ | METAP1 | P53582 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22703522 | 0.78 | TP53 (0.39) | TP53CA2METAP1CA1CA12 | |
| SCHEMBL8005394 | 0.76 | — | — | |
| SCHEMBL27672980 | 0.76 | — | — | |
| SCHEMBL776309 | 0.75 | TP53 (0.41) | TP53CA2METAP1CA1CA12 | |
| SCHEMBL4918402 | 0.74 | — | — | |
| SCHEMBL17495625 | 0.74 | TP53 (0.46) | TP53CA2CA1OPRM1SLC1A3 | |
| SCHEMBL9575743 | 0.72 | TSHR (0.36) | TP53CA2METAP1CA1CA12 | |
| SCHEMBL22811253 | 0.70 | — | — | |
| SCHEMBL222996 | 0.70 | — | — | |
| SCHEMBL3117971 | 0.70 | CA12 (0.33) | TP53CA2CA1CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180492-B2 | Anti-parasitic compounds and uses thereof | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20190002463-A1 | ANTI-PARASITIC COMPOUNDS AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2019-01-03 | — | — | US | disclosed |
| US-6713473-B1 | 6-CARBAMATE-1,2,3,4-TETRAHYDROCARBAZOLE DERIVATIVES; AFFINITY FOR NEUROPEPTIDE Y RECEPTORS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-03-30 | — | — | US | disclosed |
| EP-1184373-A1 | TRICYCLIC COMPOUNDS | MEIJI SEIKA KAISHA LTD. (JP) | 2002-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180492-B2 | Anti-parasitic compounds and uses thereof | MPO, GOT2, GOT1 | TP53 4881/4885CA2 3190/4885METAP1 579/4885 |
| US-20190002463-A1 | ANTI-PARASITIC COMPOUNDS AND USES THEREOF | MPO, GOT2, GOT1 | TP53 4881/4885CA2 3190/4885METAP1 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.